Kivu Bioscience is a biotechnology company that focuses on developing next-generation antibody-drug conjugates to target cancer.
Kivu Bioscience has raised $92.0M in total funding. The most recent round was Series A. The last funding was announced in October 2024.
Kivu Bioscience's investors include Novo Holdings, HealthCap, BioGeneration Ventures, Red Tree Venture Capital, BOM.
Kivu Bioscience is headquartered in San Francisco, United States.
Kivu Bioscience is a biotechnology company that focuses on developing next-generation antibody-drug conjugates to target cancer.
Kivu Bioscience is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kivu Bioscience — Funding & Investors." VCBacked, October 28, 2024, https://www.vcbacked.co/company/kivu-bioscience. Accessed October 30, 2026.
VCBacked. (2024). Kivu Bioscience — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/kivu-bioscience
{{cite web |title=Kivu Bioscience — Funding & Investors |url=https://www.vcbacked.co/company/kivu-bioscience |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated